Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Plymate

Showing results (61-70 of 119) with videos related to

Pageof 12
Sort By:
Contemporary Clinical Trials|April 20, 2019
Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS)Jeannette M Schenk, Marian L Neuhouser, Sarah J Beatty, et al.
The Prostate|September 16, 2004
Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumorsStephen R Plymate, Marie K Tennant, Stephen H Culp, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 15, 2005
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolitesStephanie T Page, Stephen R Plymate, William J Bremner, et al.
Oncogene|February 20, 2003
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1Stephen R Plymate, Kathy H Haugk, Cynthia C Sprenger, et al.
Cancer Research|June 20, 2012
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancerRong Hu, Changxue Lu, Elahe A Mostaghel, et al.
JCI Insight|September 11, 2019
Molecular determinants of response to high-dose androgen therapy in prostate cancerMichael D Nyquist, Alexandra Corella, Osama Mohamad, et al.
Chemical Research in Toxicology|August 19, 2007
Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screeningKevin J Coe, Yankai Jia, Han Kiat Ho, et al.
Cancer Research|June 23, 2023
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM ComplexMichael D Nyquist, Ilsa M Coleman, Jared M Lucas, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive ImpairmentAngela J Hanson, Jennifer L Bayer, Laura D Baker, et al.
Frontiers in Endocrinology|April 17, 2023
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancerSong Yi Bae, Hannah E Bergom, Abderrahman Day, et al.
Pageof 12

Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Contemporary Clinical Trials|April 20, 2019
Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS)Jeannette M Schenk, Marian L Neuhouser, Sarah J Beatty, et al.
The Prostate|September 16, 2004
Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumorsStephen R Plymate, Marie K Tennant, Stephen H Culp, et al.
American Journal of Physiology. Endocrinology and Metabolism|December 15, 2005
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolitesStephanie T Page, Stephen R Plymate, William J Bremner, et al.
Oncogene|February 20, 2003
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1Stephen R Plymate, Kathy H Haugk, Cynthia C Sprenger, et al.
Cancer Research|June 20, 2012
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancerRong Hu, Changxue Lu, Elahe A Mostaghel, et al.
JCI Insight|September 11, 2019
Molecular determinants of response to high-dose androgen therapy in prostate cancerMichael D Nyquist, Alexandra Corella, Osama Mohamad, et al.
Chemical Research in Toxicology|August 19, 2007
Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screeningKevin J Coe, Yankai Jia, Han Kiat Ho, et al.
Cancer Research|June 23, 2023
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM ComplexMichael D Nyquist, Ilsa M Coleman, Jared M Lucas, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Differential Effects of Meal Challenges on Cognition, Metabolism, and Biomarkers for Apolipoprotein E ɛ4 Carriers and Adults with Mild Cognitive ImpairmentAngela J Hanson, Jennifer L Bayer, Laura D Baker, et al.
Frontiers in Endocrinology|April 17, 2023
ZBTB7A as a novel vulnerability in neuroendocrine prostate cancerSong Yi Bae, Hannah E Bergom, Abderrahman Day, et al.
Pageof 12